© 2025 Connecticut Public

FCC Public Inspection Files:
WEDH · WEDN · WEDW · WEDY
WEDW-FM · WNPR · WPKT · WRLI-FM
Public Files Contact · ATSC 3.0 FAQ
Play Live Radio
Next Up:
0:00
0:00
0:00 0:00
Available On Air Stations

Drug makers including Pfizer are starting to sell drugs directly to consumers

AYESHA RASCOE, HOST:

Some major pharmaceutical companies are getting into the telehealth business. This could allow patients to skip a visit with their regular doctor and let companies sell their drugs directly to consumers. But is that a good idea? NPR pharmaceuticals correspondent Sydney Lupkin reports.

SYDNEY LUPKIN, BYLINE: Pfizer says it's launching a telehealth platform called Pfizer For All. Through it, consumers can get a limited selection of Pfizer products, COVID tests, vaccines, and migraine medications from start to finish. Pfizer is partnering with several existing telehealth and delivery companies, including Instacart, to fulfill orders. People can use the Pfizer site to book appointments with online healthcare providers, get prescriptions, and then fill them. Here's Dr. Ben Rome of Harvard University.

BEN ROME: That's different than, you know, typically where you have to have your prescription sent from your doctor to a pharmacy or a mail order pharmacy or an in-person brick-and-mortar pharmacy, and now they're trying to sort of cut out some of the intermediary pieces there.

LUPKIN: The Pfizer platform mirrors a similar direct-to-consumer offering Eli Lilly launched earlier this year for its diabetes, obesity and migraine drugs. Lilly said last week that it will also be offering vials of its obesity drug Zepbound at a steep discount, but only for people paying out of their own pocket and not using their insurance. Rome analyzed the Lilly health care website in an article for the medical journal JAMA. He said some patients will find the direct-to-consumer model convenient. However, there are risks that patients using drug company telehealth services could be pushed toward a drug just because it's Lilly's or Pfizer's.

ROME: We know from lots and lots of research that when there's kind of interactions between drug companies and doctors that doctors are more likely to prescribe expensive medications maybe in situations where they're not necessary.

LUPKIN: The drug companies say the telehealth providers will prescribe medicines based on what's best for patients. Dr. Robert Steinbrook, the head of health research at Public Citizen, a nonprofit consumer advocacy group, isn't so sure.

ROBERT STEINBROOK: I just don't think this is a good idea. I understand the motivations and the marketing aspects of this. But to me, it's just something which can contribute to further fragmentation of care.

LUPKIN: He says patients should go to their primary care physicians when possible. Those are the doctors who know them best, know their medical histories, and can really talk about all the health risks and benefits of a given drug as it fits into that patient's care. And sometimes, he says, physicians can offer solutions that don't involve pharmaceutical products at all.

Sydney Lupkin, NPR News. Transcript provided by NPR, Copyright NPR.

NPR transcripts are created on a rush deadline by an NPR contractor. This text may not be in its final form and may be updated or revised in the future. Accuracy and availability may vary. The authoritative record of NPR’s programming is the audio record.

Sydney Lupkin is the pharmaceuticals correspondent for NPR.

Fund the Facts

You just read trusted, local journalism that’s free for everyone, thanks to donors like you.

If that matters to you, now is the time to give. Join the 50,000+ members powering honest reporting and a more connected — and civil! — Connecticut.

SOMOS CONNECTICUT is an initiative from Connecticut Public, the state’s local NPR and PBS station, to elevate Latino stories and expand programming that uplifts and informs our Latino communities. Visit CTPublic.org/latino for more stories and resources. For updates, sign up for the SOMOS CONNECTICUT newsletter at ctpublic.org/newsletters.

SOMOS CONNECTICUT es una iniciativa de Connecticut Public, la emisora local de NPR y PBS del estado, que busca elevar nuestras historias latinas y expandir programación que alza y informa nuestras comunidades latinas locales. Visita CTPublic.org/latino para más reportajes y recursos. Para noticias, suscríbase a nuestro boletín informativo en ctpublic.org/newsletters.

Fund the Facts

You just read trusted, local journalism that’s free for everyone, thanks to donors like you.

If that matters to you, now is the time to give. Join the 50,000+ members powering honest reporting and a more connected — and civil! — Connecticut.